Moderna, Inc. financial data

Symbol
MRNA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
325 Binney Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Moderna Therapeutics, Inc. (to 8/24/2016)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 394 % +33.7%
Quick Ratio 13.1 % -27.4%
Debt-to-equity 32.5 % -3.19%
Return On Equity -17.7 % +12.8%
Return On Assets -13.4 % +12.1%
Operating Margin 4.82 % -92.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 385M shares +0.93%
Common Stock, Shares, Outstanding 385M shares +1.05%
Entity Public Float 40.2B USD -17.6%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 385M shares +1.05%
Weighted Average Number of Shares Outstanding, Diluted 399M shares +4.72%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 10.7B USD -53.7%
Revenue from Contract with Customer, Excluding Assessed Tax 5.08B USD +1.69%
Research and Development Expense 4.83B USD +3.81%
General and Administrative Expense 1.29B USD -11.1%
Costs and Expenses 7.77B USD -34%
Operating Income (Loss) -2.69B USD -1.05%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.35B USD +0.17%
Income Tax Expense (Benefit) -129M USD
Net Income (Loss) Attributable to Parent -2.22B USD +35.8%
Earnings Per Share, Basic -5.75 USD/shares +36.1%
Earnings Per Share, Diluted -5.74 USD/shares +37.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.64B USD -43.9%
Accounts Receivable, after Allowance for Credit Loss, Current 1.56B USD -16.2%
Inventory, Net 412M USD -15.4%
Other Assets, Current 46M USD -52.1%
Assets, Current 9.67B USD -10.5%
Deferred Income Tax Assets, Net 81M USD
Operating Lease, Right-of-Use Asset 784M USD +2.48%
Goodwill 52M USD 0%
Other Assets, Noncurrent 556M USD -15.9%
Assets 15.8B USD -18.8%
Accounts Payable, Current 373M USD -24.5%
Employee-related Liabilities, Current 244M USD -2.79%
Accrued Liabilities, Current 1.38B USD -38.1%
Contract with Customer, Liability, Current 379M USD -72.4%
Liabilities, Current 2.2B USD -49.8%
Contract with Customer, Liability, Noncurrent 95M USD -42.8%
Deferred Income Tax Liabilities, Net 241M USD
Operating Lease, Liability, Noncurrent 679M USD -2.58%
Other Liabilities, Noncurrent 276M USD +60.5%
Liabilities 3.88B USD -35.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 11M USD
Retained Earnings (Accumulated Deficit) 11.2B USD -16.6%
Stockholders' Equity Attributable to Parent 11.9B USD -11.4%
Liabilities and Equity 15.8B USD -18.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -989M USD +19.3%
Net Cash Provided by (Used in) Financing Activities 14M USD
Net Cash Provided by (Used in) Investing Activities 118M USD -94.1%
Common Stock, Shares Authorized 1.6B shares 0%
Common Stock, Shares, Issued 385M shares +1.05%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -857M USD -451%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.65B USD -44.2%
Deferred Tax Assets, Valuation Allowance 2.22B USD +1335%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 2.68B USD +96%
Operating Lease, Liability 700M USD -4.11%
Payments to Acquire Property, Plant, and Equipment 196M USD +73.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2B USD +39.8%
Lessee, Operating Lease, Liability, to be Paid 1.16B USD -5.07%
Operating Lease, Liability, Current 21M USD -36.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 73M USD -8.75%
Lessee, Operating Lease, Liability, to be Paid, Year One 71M USD -30.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) -146M USD -192%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 461M USD -6.49%
Lessee, Operating Lease, Liability, to be Paid, Year Three 78M USD -4.88%
Deferred Tax Assets, Operating Loss Carryforwards 90M USD +52.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 162M shares 0%
Unrecognized Tax Benefits 231M USD +80.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 81M USD -3.57%
Additional Paid in Capital 751M USD +171%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 329M USD -33.4%
Deferred Tax Assets, Net of Valuation Allowance 454M USD -62.5%
Share-based Payment Arrangement, Expense 404M USD +40.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%